Fine Organic
Fine Organic Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q3 FY26 call signalled
1 of 3 strong
The short version
For FY 2026-27 and 2027-28, revenue growth is expected to be very flat due to full capacity utilization and delays in expansion projects, especially the SEZ plant commissioning. - Growth during this period, if any, will largely be driven by price increases rather than volume growth. - Post FY 2028, meaningful growth is anticipated once the SEZ plant and U.S. FY'27 and FY'28 expected to have very flat top-line growth due to current full-capacity utilization until the SEZ plant is commissioned. - Growth in FY'27-FY'28 will primarily come from price increases, not volume growth. - Post-FY'28, growth is anticipated once SEZ and U.S.
From Fine Organic's Q3 FY26 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- For FY 2026-27 and 2027-28, revenue growth is expected to be very flat due to full capacity utilization and delays in expansion projects, especially the SEZ plant commissioning.
- Growth during this period, if any, will largely be driven by price increases rather than volume growth.
- Post FY 2028, meaningful growth is anticipated once the SEZ plant and U.S. plant become operational, enabling capacity expansion.
- Historical trends show phased growth patterns: periods of capex followed by 1-2 years of strong growth, then flat growth until new capacities are fully utilized.
- Domestic demand remains stable with no envisaged drop despite inflation.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Fine Organic said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Fine Organic Industries has ongoing and planned capital investments including:
- SEZ Plant in India:
- Investment of approximately INR 700-750 crores for Phase 1.
- Construction recently started; commissioning expected in second half of FY 2028.
- U.S. Plant:
- Land acquired; contractor finalization in progress.
- Planned as a world-scale facility in multiple phases (3 phases planned).
- First phase to be conservative in size; commissioning expected within 18-24 months after construction start.
- Investment figure to be announced next quarter.
- Oleofine Organics Acquisition:
- 80% share acquisition completed; current revenue approx INR 54 crores.
- Plans underway to expand this palm-based food additives business.
- Other Expansion Plans:
- Thailand JV expansion planned but delayed due to SEZ focus.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fine Organic said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is currently focusing on short-term contracts with customers, especially due to raw material price volatility and supply chain challenges.
- Long-term contracts are not being entered into at present to remain flexible amid unstable raw material prices; customers are cooperating with shorter contract durations (1-3 months).
- Existing plants are running at almost full capacity, prioritizing domestic customers and managing export demands accordingly.
- New capacities such as the SEZ plant and U.S. plant are under construction but not yet commissioned; once operational, they are expected to accommodate incremental demand.
2 more points management made on order book & pipeline
Fine Organic — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹625 Cr, net profit ₹117 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fine Organic Industries Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Bodal Chemicals Ltd (Q3 FY26)
5,046.6 Mn, up 13.3% YoY (Q3 FY25: Rs. Key concall takeaways from Bodal Chemicals Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Rain Industries (Q3 FY26)
Capacity utilization levels across segments position the company well for incremental growth: Carbon plants at ~70%, Advanced Materials at ~60%, Cement at ~65%…
- Prem. Explosives (Q3 FY26)
Major revenue contributors in FY '27: chaffs and flares orders (~INR430 crores) and explosive sales (RDX and HMX ~INR150 crores). Key concall takeaways from…
- Sudarshan Chem. (Q3 FY26)
Interest cost on borrowings is currently around 5.75% to 6% (excluding IndAS lease accounting costs). Key concall takeaways from Sudarshan Chemical Industries…
Frequently Asked Questions
What were Fine Organic Q3 FY26 results?
For FY 2026-27 and 2027-28, revenue growth is expected to be very flat due to full capacity utilization and delays in expansion projects, especially the SEZ plant commissioning. - Growth during this period, if any, will largely be driven by price increases rather than volume growth. - Post FY 2028, meaningful growth is anticipated once the SEZ plant and U.S. FY'27 and FY'28 expected to have very flat top-line growth due to current full-capacity utilization until the SEZ plant is commissioned. - Growth in FY'27-FY'28 will primarily come from price increases, not volume growth. - Post-FY'28, growth is anticipated once SEZ and U.S.
What is Fine Organic share price analysis?
Fine Organic currently shows a neutral. The stock trades at a P/E of 36.1 with a market cap of ₹15,820 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fine Organic planning capital expenditure?
Fine Organic Industries has ongoing and planned capital investments including: - SEZ Plant in India: - Investment of approximately INR 700-750 crores for Phase 1. - Construction recently started; commissioning expected in second half of FY 2028. - U.S.
Keep Fine Organic on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.